Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Median Technologies

< Previous 1 2 3 Next >
News headline image
Median Technologies Reports Record iCRO Backlog, Accelerates Commercial Rollout of eyonis® LCS and Development of New Indications Across the eyonis® Portfolio
From Median Technologies
Via Business Wire
News headline image
Median Technologies’ eyonis® LCS Obtains CE Marking
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Showcase iCRO’s Central and AI-powered Imaging Services for Oncology Clinical Trials at ASCO 2026
From Median Technologies
Via Business Wire
News headline image
Median Technologies Reports Full-Year 2025 Financial Results and Provides Key Q1 2026 Business Highlights
From Median Technologies
Via Business Wire
News headline image
Median Technologies Achieves ISO 13485:2016 Certification for eyonis® Medical Device Quality Management System
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology
From Median Technologies
Via Business Wire
News headline image
Median Technologies to present at the TD Cowen 46th Annual Health Care Conference
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Host Webcasts Highlighting Strategic Advances Driving U.S. Deployment of eyonis® LCS
From Median Technologies
Via Business Wire
News headline image
FDA Clearance Sets Stage for U.S. Commercialization of eyonis® LCS Software as a Medical Device for Lung Cancer Screening; Oran Muduroglu Appointed President of Median eyonis Inc.
From Median Technologies
Via Business Wire
News headline image
Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
From Median Technologies
Via Business Wire
News headline image
Median Technologies Receives FDA 510(k) Clearance for eyonis® LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening
From Median Technologies
Via Business Wire
News headline image
Median Technologies Reports Landmark 2025 Performance With Major Regulatory and Commercial Milestones Ahead in 2026
From Median Technologies
Via Business Wire
News headline image
Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis® LCS to Patients Across the U.S. and Europe
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Showcase AI-Powered Software as a Medical Device eyonis® LCS for Lung Cancer Screening at the RSNA 2025 Annual Meeting
From Median Technologies
Via Business Wire
News headline image
Median Technologies Appoints Didric Cederholm to Its Board of Directors
From Median Technologies
Via Business Wire
News headline image
Median Technologies Reports First-Half 2025 Financial Results and Provides Key Q3 2025 Business Results
From Median Technologies
Via Business Wire
News headline image
Median Technologies Receives €19 Million From the European Investment Bank, Corresponding to the First Tranche Under the 2025 Loan Facility
From Median Technologies
Via Business Wire
News headline image
Median Technologies Business Update Following Successful Financing
From Median Technologies
Via Business Wire
News headline image
Median Technologies Signs Financial Agreement for up to €37.5 Million New Financing Facility With the European Investment Bank (EIB)
From Median Technologies
Via Business Wire
News headline image
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ASCO 2025
From Median Technologies
Via Business Wire
News headline image
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
From Median Technologies
Via Business Wire
News headline image
Median Technologies Reports Full-year 2024 Financial Results
From Median Technologies
Via Business Wire
News headline image
Median Technologies Reports 2025 Q1 Key Financial Indicators and Provides an Update on Q1 Key Operational Achievements
From Median Technologies
Via Business Wire
News headline image
eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference
From Median Technologies
Via Business Wire
News headline image
Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
From Median Technologies
Via Business Wire
News headline image
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
From Median Technologies
Via Business Wire
News headline image
Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
From Median Technologies
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.